Drug intelligence / Profile preview

insulin + propranolol

Development stage: Unknown
Lead developer: Novo Nordisk
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Subcutaneous, Oral, Intravenous

Overview

A combination of insulin and propranolol. Insulin is a hormone used to treat diabetes mellitus by promoting glucose uptake from the blood into cells. Propranolol is a non-selective beta-adrenergic antagonist (beta-blocker) used to treat various conditions including hypertension, angina, atrial fibrillation, and migraines. When used together, propranolol may increase the risk, severity, and duration of hypoglycemia in patients receiving insulin by masking some warning signs of low blood sugar and potentially enhancing insulin's blood-glucose-lowering effects.

Targets

ADRB3 (β3)ADRB1 (β1)INSR (Insulin receptor)ADRB2 (β2)SOX18

Beyond the preview

Go deeper on insulin + propranolol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on insulin + propranolol.

Explore the full profile